All AI training jobs

Mercor · Open to all

Disease-Area Clinician — Trial Endpoints & Prescribing

Listed on Mercor as “Disease-Area Clinician - Trial Endpoints & Prescribing

$150-$230/hrRemoteContractPaid in USD
ShareWhatsAppTelegramEmail

What this actually is

You complete short labeling tasks, record everyday activities, or evaluate AI outputs across general knowledge domains. Open to most backgrounds. The platform title (Disease-Area Clinician - Trial Endpoints & Prescribing) reflects the rate band and the expertise required, not the day-to-day work.

Advertisement

Can you do this on your visa?

F-2 / F-4 / F-5 / F-6: open. E-1 to E-7: needs concurrent-employment permit. D-2 / D-4 students: S-3 permit, 20 hr/week cap. D-10 / D-8: case by case.

Korean tax on USD income

First 5 years in Korea: foreign-source income only taxed if remitted into Korea. After year 5: worldwide income. Full tax guide.

Original posting from Mercor

Mercor is partnering with a biotech and pharma research team on expert human-evaluation work - creating and critiquing rubrics that analyze commercial drugs and drug-development programs. We're seeking a disease-area clinician for a paid pilot, with the potential to continue as the work scales.

Responsibilities

  • Create and critique rubrics that analyze commercial drugs and drug-development programs
  • Interpret clinical trial endpoints and judge whether results would change prescribing
  • Assess what that means for real-world uptake in your therapeutic area
  • Apply this across the pilot's set of drugs and programs

Requirements

  • US-based disease-area clinician (practising physician, MD/DO)
  • Familiarity with biotech/pharma development programs
  • Deep expertise in a specific therapeutic area
  • Board-certified and actively practising in your specialty

Engagement Details

  • Duration: Approximately 10-20 hours over a 1-2 week pilot
  • Remote - US-based

Why Participate

  • Help improve expert AI evaluation of drugs and drug-development programs
  • Recurring engagement for strong contributors

Quoted from Mercor’s public listing on 2026-09-08. We don’t edit platform copy; honest framing is in the title and the “what this actually is” block above.

Apply on Mercor